Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus Macaques. by Lo, Ming et al.
UC Davis
UC Davis Previously Published Works
Title
Acute Infection and Subsequent Subclinical Reactivation of Herpes Simplex Virus 2 
after Vaginal Inoculation of Rhesus Macaques.
Permalink
https://escholarship.org/uc/item/3v9675m5
Journal
Journal of Virology, 93(2)
ISSN
0022-538X
Authors
Lo, Ming
Zhu, Jia
Hansen, Scott G
et al.
Publication Date
2019-01-04
DOI
10.1128/JVI.01574-18
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Acute Infection and Subsequent Subclinical Reactivation of
Herpes Simplex Virus 2 after Vaginal Inoculation of Rhesus
Macaques
Ming Lo,a,b Jia Zhu,c,d Scott G. Hansen,e,f Timothy Carroll,a,b Christina Farr Zuend,g,h Laura Nöel-Romas,g,h Zhong-Min Ma,a,b
Linda Fritts,a,b Meei-Li Huang,c Sijie Sun,c Ying Huang,c David M. Koelle,c,d,i Louis J. Picker,e,f Adam Burgener,g,h,j
Lawrence Corey,c,d,i Christopher J. Millera,b
aCenter for Comparative Medicine, University of California Davis, Davis, California, USA
bCalifornia National Primate Research Center, University of California Davis, Davis, California, USA
cDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA
dVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
eVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, USA
fOregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA
gNational HIV and Retrovirology Labs, J.C. Wilt Infectious Disease Research Centre, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
hUniversity of Manitoba, Winnipeg, Manitoba, Canada
iDepartment of Medicine, University of Washington, Seattle, Washington, USA
jUnit of Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
ABSTRACT Herpes simplex virus 2 (HSV-2) is a common sexually transmitted infec-
tion with a highly variable clinical course. Many infections quickly become subclini-
cal, with episodes of spontaneous virus reactivation. To study host–HSV-2 interac-
tions, an animal model of subclinical HSV-2 infection is needed. In an effort to
develop a relevant model, rhesus macaques (RM) were inoculated intravaginally with
two or three HSV-2 strains (186, 333, and/or G) at a total dose of 1 107 PFU of
HSV-2 per animal. Infectious HSV-2 and HSV-2 DNA were consistently shed in vaginal
swabs for the first 7 to 14 days after each inoculation. Proteins associated with
wound healing, innate immunity, and inflammation were significantly increased in
cervical secretions immediately after HSV-2 inoculation. There was histologic evi-
dence of acute herpesvirus pathology, including acantholysis in the squamous epi-
thelium and ballooning degeneration of and intranuclear inclusion bodies in epithe-
lial cells, with HSV antigen in mucosal epithelial cells and keratinocytes. Further, an
intense inflammatory infiltrate was found in the cervix and vulva. Evidence of latent
infection and reactivation was demonstrated by the detection of spontaneous HSV-2
shedding post-acute inoculation (102 to 103 DNA copies/swab) in 80% of RM. Fur-
ther, HSV-2 DNA was detected in ganglia in most necropsied animals. HSV-2-specifc
T-cell responses were detected in all animals, although antibodies to HSV-2 were de-
tected in only 30% of the animals. Thus, HSV-2 infection of RM recapitulates many
of the key features of subclinical HSV-2 infection in women but seems to be more
limited, as virus shedding was undetectable more than 40 days after the last virus
inoculation.
IMPORTANCE Herpes simplex virus 2 (HSV-2) infects nearly 500 million persons
globally, with an estimated 21 million incident cases each year, making it one of the
most common sexually transmitted infections (STIs). HSV-2 is associated with in-
creased human immunodeficiency virus type 1 (HIV-1) acquisition, and this risk does
not decline with the use of antiherpes drugs. As initial acquisition of both HIV and
HSV-2 infections is subclinical, study of the initial molecular interactions of the two
agents requires an animal model. We found that HSV-2 can infect RM after vaginal
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inoculation, establish latency in the nervous system, and spontaneously reactivate;
these features mimic some of the key features of HSV-2 infection in women. RM
may provide an animal model to develop strategies to prevent HSV-2 acquisition
and reactivation.
KEYWORDS female reproductive tract, T-cell responses, cervix, herpes simplex virus,
proteomics, subclinical infection, vaginal swabs
Herpes simplex virus 2 (HSV-2) infection is a common chronic viral sexually trans-mitted infection (STI) of humans. In 2012, an estimated 417 million people were
infected with HSV-2, and nearly 300 million of these were women (1). Further, there
were estimated to be 12 million incident cases among women that year (1). HSV-2 was
one of the opportunistic infections described in the original report of AIDS (2, 3). In
1988, Stamm et al. reported an increase of human immunodeficiency virus type 1
(HIV-1) infections among men who have sex with men (MSM) with incident and
prevalent HSV-2 (4). Extension of these data to female populations throughout the
world was noted in the early 1990s, and epidemiologic studies suggest that HSV-2
increases the per-contact rate of HIV-1 acquisition in women 3-fold (5). In regions of
high HSV-2 prevalence, it is estimated that 25 to 35% of HIV incidence is directly
attributable to HSV-2 infections (5, 6). Subclinical HSV-2 reactivation occurs in over 90%
of HSV-2-seropositive persons (7). The immune cell populations that respond to control
HSV-2 reactivation in genital tissues express surface receptors for HIV (8), which may
explain enhanced HIV acquisition in HSV-2 women.
As both HIV-1 and HSV-2 infections can be acquired subclinically, studies of the
molecular interactions of the two agents require an animal model. Mouse models of
vaginal HSV-2 infection are available, but unlike human infection, they result in a lethal
acute disease (reviewed in reference 9). Moreover, HSV-2 does not spontaneously
reactivate in mice. Spontaneous reactivation from latency occurs in dorsal root ganglia
of guinea pigs (GP), providing a useful model to study the virology of HSV-2 latency
(reviewed in reference 9); however, reagents to study HSV-2 immunopathogenesis in
GP are limited.
Simian immunodeficiency virus (SIV) infection in rhesus macaques (RM) is a valuable
animal model for HIV pathogenesis studies, but prior attempts to infect RM with HSV
have largely failed (10, 11). In fact, RM appear to be less susceptible to HSV infection
than some NewWorld primates (10, 11). The relative resistance of RM to HSV-2 infection
is likely because TRIM5a expression in RM cells partially blocks HSV-2 replication in vitro
(12). In 2009, Crostarosa et al. reported that after experimental vaginal HSV-2 inocula-
tion, RM became infected and HSV-2 DNA shedding in genital secretions was subse-
quently detected (13). Further, enhanced vaginal transmission of simian-human immu-
nodeficiency virus (SHIV) was reported for HSV-2-infected RM without genital lesions
(13). This study, while useful conceptually, reported limited data on neuronal latency,
the virological characteristics of reactivation, and the immune responses to HSV-2.
Thus, the utility of the RM for modeling HSV-2 infection remains unclear (12). The goal
of the current study was to characterize HSV-2 infection in RM using the same assays
and sampling methods that have been used for humans to provide a much more
detailed understanding of HSV-2 infection in this animal model (14–18).
RESULTS
Acute HSV-2 infection. Four mature female RM (group 1) were inoculated intra-
vaginally with 1 ml of a 1:1 mixture of 2 HSV-2 strains (strains 186 and 333; total titer
of 107 PFU) on days 0, 7, 14, 21, and 56 (Fig. 1). As we are unsure if there was a
difference in the abilities of different HSV-2 strains to infect RM, we used a mixture of
HSV-2 strains for the inoculations. Infectious virus and HSV-2 DNA were consistently
detected in secretions of all 4 animals for the first 7 days after every inoculation (Fig. 1A
and B). HSV-2 DNA was detected in all vaginal swabs taken within 7 days of the initial
intravaginal inoculation (Fig. 1A), and replication-competent HSV-2 was isolated in
Lo et al. Journal of Virology
January 2019 Volume 93 Issue 2 e01574-18 jvi.asm.org 2
FIG 1 HSV-2 shedding in cervicovaginal secretions of rhesus macaques after HSV-2 inoculation (group 1). Each of the four female rhesus macaques was
intravaginally challenged with total 1 107 PFU of HSV-2 in 1 ml of inoculum containing a 1:1 mixture of HSV-2 186 and HSV-2 333 once a week for 4
(Continued on next page)
HSV-2 in Rhesus Macaques Journal of Virology
January 2019 Volume 93 Issue 2 e01574-18 jvi.asm.org 3
tissue culture on 30 of the 78 (38%) samples submitted for virus isolation during the
same period (Fig. 1B). As expected, HSV-2 DNA was detected in all genital secretion
samples that were viral isolation positive. HSV-2 DNA detection decreased nearly
linearly (107 to 102 copies/swab) over the first 10 to 14 days postinoculation. The titer
and duration of HSV-2 DNA shedding in secretions were similar after each of the initial
4 weekly HSV-2 inoculations. Clinically, no genital lesions, fever, or change in appetite,
behavior, or bowel or motor functions were noted postinoculation. Importantly, spon-
taneous subclinical shedding of HSV-2 DNA (102 to 103 copies/swab) was detected in
secretions collected between day 42 (outside the acute phase of intense virus shed-
ding) and day 56 (Fig. 1A) in 3 of the 4 animals. HSV-2 DNA was intermittently shed in
the secretions of these 3 animals during this period. The duration of each shedding
episode was less than 1 day, meaning that DNA was detected in only one of the two
swabs collected 8 h apart on that day (Fig. 1A) and was at titers of 102 to 103, as seen
with subclinical shedding in humans (14, 16). The animals were necropsied 7 to 17 days
after the last HSV-2 inoculation on day 56.
A real-time PCR assay that distinguishes between HSV-2 strains 186 and 333 was
used to identify the viruses present in genital secretions during the acute phase of
high-level HSV-2 DNA shedding (Fig. 1C). In almost all samples tested, both strains were
detected; HSV-2 strain 186 was somewhat more common, especially at later time
points.
Histologic evidence of active HSV-2 infection in the genial tract tissue was found in
genital tissue collected by biopsy at day 7 postinoculation (p.i.) and at necropsy 7 to
17 days after the last HSV-2 inoculation (Fig. 2 and 3). In the cervical biopsy specimens
from all 4 animals collected at 7 days p.i. there were multifocal areas where the
overlying epithelium was lost or degenerating and widespread acantholysis and de-
generation of epithelial cells (Fig. 2A and B). In some areas the upper layers of the
epithelium were lost, and in other areas clefts were forming between epithelial layers
(Fig. 2C and D). These are both changes consistent with different stages in the
formation and rupture of fluid-filled vesicles. The cytopathic changes in the epithelium
were associated with an intense inflammatory cell infiltrate, comprised mainly of
mononuclear cells with fewer neutrophils, surrounding small blood vessels in the
lamina propria and extending into the columnar epithelium of the endocervix and the
stratified squamous epithelium of the ectocervix. Lymphatic vessels in the lamina
propria were distended with inflammatory cells and fluid (Fig. 2A and B). Importantly,
HSV-2 antigen was detected in the epithelium in both the vagina and cervix (Fig. 2E).
Areas with HSV-2 antigen had a dense CD8 T-cell infiltrate (Fig. 2E). A complete
examination of the genital tract at necropsy 7 to 17 days after the last HSV-2 inoculation
on day 56 revealed no evidence of herpetic ulcers. However, on histologic examination,
all 4 animals had a chronic cervicitis and vaginitis characterized by multiple, variably
spaced, focal areas of inflammation (Fig. 3A). The cellular infiltrate associated with the
inflammation was largely mononuclear and was focused on areas of epithelial cell
degeneration and acantholysis. In addition, epithelial cells with the eosinophilic (red)
intranuclear inclusion bodies and marginated chromatin, which are characteristic cy-
topathic effects of herpesvirus infections, were common in these areas (Fig. 3B). Even
in areas of the vaginal mucosa with little inflammation (Fig. 3C), HSV-2 antigen was
found in a few basal epithelial cells and, rarely, in mononuclear cells in the lamina
propria (Fig. 3D and E). Both CD4 and CD8 T cells were numerous in the vaginal
mucosa of these chronically HSV-2-infected animals (Fig. 3F). Cervical biopsy specimens
collected at day 7 after the initial inoculation in the 4 animals in group 1 revealed HSV
FIG 1 Legend (Continued)
weeks. After a 5-week interval, the animals were reinoculated with the same HSV-2 mixture and necropsied 1 to 2 weeks later. Twice-daily vaginal swabs
were collected (except weekends) after the first HSV-2 inoculation. Animal numbers are indicated and color-coded to matched graphed data. (A) Results
of PCR to quantitate HSV-2 gB DNA levels in vaginal swabs. (B) Results of attempt to isolate infectious HSV-2 from vaginal swabs by tissue culture. (C)
Ratio of HSV-2 strains in the cervicovaginal secretions. PCR was used to differentiate the strains of HSV-2 detected in secretions. HSV-2 strain 333 levels
were used as a baseline (white bars, ratio of 333 to 333 1), the ratio of HSV-2 186 levels to HSV-2 333 levels is shown by gray bars.
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DNA in tissue at high copy numbers (1,100 to 5,400 copies/million cells), while none of
the cervical biopsy specimens taken at day 28 from the 6 RM in group 2 were HSV-2
DNA positive (Table 1). Thus, evidence of genital tissue infection, viral replication, and
an associated inflammatory response was seen histologically at 7 days p.i.
To evaluate whether subclinical reactivation occurs in RM, we intravaginally inocu-
lated 6 additional animals (group 2) with HSV-2 twice, on day 0 and day 28 (Fig. 4A).
Four of the 6 RM were inoculated intravaginally with 1 ml of a 1:1 mixture of 2 HSV-2
strains (186 and 333; total titer of 107 PFU), and 2 of the 6 RM were inoculated with 1 ml
of a 1:1:1 mixture of 3 HSV-2 strains (G, 186, and 333; total titer of 107 PFU) (Fig. 4A).
As before, HSV-2 DNA was consistently detected in secretions of all 6 animals for
approximately the first 10 days after every inoculation (Fig. 4A). Importantly, sponta-
neous HSV-2 reactivation as detected by HSV-2 DNA (102 to 103 copies/swab) in swabs
occurred in 5 of the 6 animals during the 14- to 28- and 35- to 100-day postinoculation
periods (Fig. 4A). The duration of shedding episodes ranged from less than 1 day to
2 days (Fig. 4A), a pattern of intermittent subclinical shedding that is similar to that seen
FIG 2 Histopathology and localization of HSV-2 antigen and CD8 T cells in cervical biopsy tissue
obtained 2 and 7 days after vaginal HSV-2 inoculation. Panels A and B show formalin-fixed paraffin-
embedded sections of a cervical biopsy specimen collected at 2 days p.i. (A) H&E stain of ectocervix. The
overlying epithelium is intact but is compromised by microvesicles and clefts filled with fibrin and cellular
debris. Inflammatory cell infiltrates surround small blood vessels in the lamina propria and extend into
the stratified epithelium of the ectocervix. Lymphatic vessels in the lamina propria are distended with
inflammatory cells and edema fluid. (B) Higher magnification of the inset from panel A. The inflammatory
cell infiltrate is focused on the epithelium and is comprised mainly of mononuclear cells, with fewer
neutrophils. There is widespread acantholysis in the stratified squamous epithelium, with ballooning
degeneration of epithelial cells. The microvesicles within the epithelium contain fibrin, cell debris,
acantholytic epithelial cells, and inflammatory cells. Many of the epithelial cells at the edge of the
microvesicles have large ground-glass nuclei with marginated chromatin. Panels C, D, and E show frozen
sections of a cervical biopsy specimen collected at 7 days p.i. (C) H&E stain of the transformation zone
at the border of the endocervix and ectocervix. Much of the overlying epithelium is lost or degenerating,
replaced by fibrin, inflammatory cells, and cellular debris. The remaining epithelium contains acellular
areas filled with fibrin, cellular debris, and edema. Inflammatory cell infiltrates surround small blood
vessels in the lamina propria and extend into the columnar epithelium of the endocervix and the
stratified squamous epithelium of the ectocervix. Lymphatic vessels in the lamina propria are distended
with inflammatory cells and fluid. (D) Higher magnification of the inset from panel C. The inflammatory
cell infiltrate is focused on the epithelium and is comprised mainly of mononuclear cells, with fewer
neutrophils. There is widespread acantholysis in the stratified squamous epithelium, with ballooning
degeneration of epithelial cells. The arrows indicate microvesicles within the epithelium that contain
fibrin, cell debris, and inflammatory cells. (E) Immunofluorescent staining for HSV-2 antigen (green) and
CD8 T cells (red). Note that the HSV-2 antigen is expressed in the middle layer of the epithelium by
acantholytic or detached epithelial cells at the edge of intraepithelial vesicles.
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in women with HSV-2 (19, 20). However, the frequency of shedding decreased as the
interval after inoculation increased, and the last DNA-positive samples were collected
at 60 days p.i., 32 days after the final HSV-2 inoculation (Fig. 4A).
Effect of medroxyprogesterone acetate administration on HSV-2 infection of
RM. Pretreatment with exogenous progestins, such as medroxyprogesterone acetate
(Depo-Provera), has been reported to facilitate vaginal HSV-2 infection of mice and
FIG 3 Histopathology and localization of HSV-2 antigen and T cells in vaginal mucosa obtained at necropsy.
(A and B) Images are from a region of vaginal mucosa with obvious histopathology. (A) Within the
squamous epithelium and lamina propria there were multiple focal areas with mononuclear inflammatory
cell infiltrates. In the lamina propria, the inflammatory cells surrounded small blood and lymphatic vessels
that were distended by edema. In the stratified squamous epithelium, the inflammatory cell infiltrates were
focused in areas with acantholytic and degenerating epithelial cells. (B) Higher magnification of the inset
from panel A. There is widespread acantholysis in the stratified squamous epithelium with ballooning
degeneration of epithelial cells. The arrows indicate some of the numerous eosinophilic (red) intranuclear
inclusion bodies and marginated chromatin within epithelial cells that are characteristic of herpesvirus
infection. (C to F) Images are from a region of the vaginal mucosa with mild histopathology. (C) Normal
epithelium with numerous layers characteristic of the follicular phase of the menstrual cycle. There is a mild
mononuclear cell infiltrate with edema centered on the basal epithelial layer, superficial lamina propria, and
around small vessels. Lymphatic vessels are distended with fluid. (D and E) Immunofluorescent staining for
HSV-2 antigen (green) and CD8 T cells (red). HSV-2 antigen is expressed in a few basal epithelial cells and
mononuclear cells in the lamina propria (arrows). (F) Immunofluorescent staining for CD4 (green) and
CD8 (red) T cells.
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SIV/SHIV infection in RM because it increases epithelial permeability and thins the
stratified squamous epithelium by removing the cornified layers (21). To determine if
medroxyprogesterone acetate markedly altered HSV-2 infection in RM, medroxypro-
gesterone acetate (30 mg/animal) was administered to 4 animals (group 3) by intra-
muscular injection 30 days prior to, and on the day of, the first intravaginal inoculation
with 1 ml of a 1:1:1 mixture of 3 HSV-2 strains (G, 186, and 333; total titer of 107 PFU).
The animals were challenged with HSV-2 twice, separated by 28 days (Fig. 4B). The
pattern of HSV-2 DNA shedding was similar to that of the no-medroxyprogesterone
acetate group 2 animals; viral DNA (vDNA) was consistently detected in secretions of
all 4 animals for 7 to 14 days after every inoculation (Fig. 4B). As with the no-
medroxyprogesterone acetate group 2 animals, spontaneous HSV-2 DNA (102 to 103
copies/swab) was documented in 3 of 4 medroxyprogesterone acetate-treated animals
during the 14- to 28- and 35- to 100-day postinoculation periods. During these periods,
the duration of shedding was never more than 24 h (Fig. 4B) and the frequency of
shedding decreased over time, with the last HSV-2 DNA samples collected at 60 days
p.i. (32 days after the final HSV-2 inoculation). Thus, although our sample size was small,
medroxyprogesterone acetate did not markedly alter the pattern of acute HSV-2
shedding or subsequent HSV-2 reactivation in RM.
Effect of transient CD8 chain-positive lymphocyte (T cell and NK cell) deple-
tion on HSV-2 infection of RM. NK cells can recognize decreased surface expression
of major histocompatibility complex class I (MHC-I) on virus-infected cells immediately
after infection, and kill these cells, before adaptive immune responses have developed.
To determine the effect of naive CD8 T cells and NK cells on HSV-2 infection in RM,
a anti-CD8 chain-depleting monoclonal antibody (MAb) and an interleukin 15 (IL-15)-
depleting MAb were administered by intravenous (i.v.) injection to 2 animals (group 4)
by subcutaneous injection 3 days prior to, and on the day of, intravaginal inoculation
with 1 ml of a 1:1:1 mixture of 3 HSV-2 strains (G, 186, and 333; total titer of 107 PFU).
While all CD8 cells (T cells and NK cells) in blood were completely depleted (data not
shown), we and others have previously shown that approximately 20% of CD8 cells
in mucosal tissues persist after anti-CD8 MAb administration (22). The animals were
challenged with HSV-2 twice, separated by 28 days (Fig. 4C). The pattern of HSV-2 DNA
shedding was similar to that in the untreated group 2 animals and the medroxypro-
gesterone acetate-treated group 3 animals; vDNA was consistently detected in secre-
TABLE 1 HSV-2 DNA in tissues of HSV-2-inoculated rhesus macaques
Tissue
No. of copies of HSV-2 DNA/million cells in indicated animal
Group 1
(live virus inoculum) Group 2 (live virus inoculum)
Group 5
(killed virus inoculum)
34806 34889 35667 38420 33869 35633 37957 34099 39406 33991 40257 38044 37349
Cervical biopsya 1,147 2,184 5,448 3,271 0 0 0 0 0 0 346 0 68
Vulvab 0 0 38 3,270 20,543 3,871 434 2,901 185 185 0 0 0
Cervixb 0 51 144 0 204 581 936 51 128 0 0 0 0
Vagina 1b,c 3,376 155 0 608 16,855 1,004 863 133 63 76 0 0 0
Vagina 2b,d 1,803 188 0 212 3,745 4,400 1,208 252 133 0 0 0 0
Vagina 3b,e 0 0 0 0 332 1,283 1,449 293 117 642 0 0 0
Cervical ganglia/cordb 0 7,719 0 915 0 147 0 64 0 0 0 0 0
Thoracic ganglia/cordb 0 0 0 6,946 0 0 0 0 0 0 0 0 0
Lumbar ganglia/cordb 0 0 0 0 425 0 0 3,043 68 0 0 0 0
Sacral ganglia/cordb 0 0 0 0 0 0 0 0 0 0 0 0 0
Pelvic nerve 656 0 0 0 0 0 0 0 0 0 0 0 0
Sacral systemic trunk NDf ND ND ND 1,590 0 0 0 0 0 0 0 0
aBiopsy specimens were collected 7 days after the first HSV-2 inoculation for group 1, 28 days after the first HSV-2 inoculation for group 2, and 2 or 3 days after the
first heat-killed HSV-2 inoculation for group 5.
bNecropsy tissue collected 2 to 7 days after the last HSV-2 inoculation.
cProximal vaginal mucosa (fornix).
dMid-vaginal mucosa.
eDistal vaginal mucosa (introitus).
fND, not determined.
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tions from both animals for 7 to 14 days after every inoculation (Fig. 4C). Spontaneous
HSV-2 DNA shedding (102 to 103 copies/swab) that persisted for less than 24 h was
detected in the animals during the 14- to 28- and 35- to 100-day postinoculation
periods, and the last HSV-2 DNA-positive cervicovaginal secretion (CVS) sample was
collected 64 days p.i. (36 days after the final HSV-2 inoculation) (Fig. 4C). These data
suggest no dramatic difference in HSV-2 shedding with this form of CD8 T-cell
depletion.
Shedding of HSV-2 DNA after vaginal inoculation of RM with heat-inactivated
virus. Three animals (group 5) were intravaginally inoculated twice (days 0 and 28) with
1 ml of a 1:1:1 mixture of 3 heat-inactivated HSV-2 strains (G, 186, and HSV-2 333; total
titer of 107 PFU) (Fig. 4D). None of the samples collected for viral isolation between days
1 and 3 had HSV isolated in tissue culture. However, HSV-2 DNA was detected in swab
samples in the first week after inoculation with heat-inactivated virus. Importantly,
histologic examination of the tissues revealed no evidence of cytopathology in the
vulva and cervix in the heat-inactivated virus-inoculated animals, and spontaneous
HSV-2 reactivation as determined by vDNA shedding was never detected during the 14-
to 28- and 35- to 100-day postinoculation periods in these 3 animals (Fig. 4D). As
discussed below, no evidence of neuronal HSV infection was seen at necropsy of
animals inoculated with heat-killed HSV-2 (Table 1).
To compare the levels of HSV-2 DNA shedding after vaginal inoculation of RM with
heat-inactivated virus and live HSV-2, the area under the curve (AUC) and decay rate of
the HSV-2 DNA level in secretions for each animal over time intervals specified in
FIG 4 Spontaneous reactivation of HSV-2 in RM is detected after infectious viral challenge but not after heat-inactivated HSV-2 challenge. (A) Four
of the six female monkeys in group 2 were intravaginally inoculated with a mixture of HSV-2 strains 186 and 333 (total of 1 107 PFU in the 1-ml
inoculum) (solid lines and solid symbols); the remaining 2 animals were inoculated with a mixture of HSV-2 strains 186, 333, and G (dashed lines
and open symbols). Inoculations were separated by 28 days. (B) Group 3. These 4 animals were treated with medroxyprogesterone acetate and
then inoculated 2 times with HSV-2 (days 0 and 28). (C) Group 4. These 2 animals were treated with a depleting antibody that targets CD8
lymphocytes (T cells and NK cells) and then inoculated 2 times with HSV-2 (days 0 and 28). (D) Group 5. These three female monkeys were
intravaginally inoculated with a mixture of heat-killed HSV-2 strains 186, 333, and G (1 107 PFU of HSV-2/ml prior to inactivation). Note that 11
of 12 RM inoculated with live HSV-2, but none of the 3 animals inoculated with heat-killed HSV-2, shed HSV-2 DNA in genital secretions at least
once between days 14 to 28 and 35 to 49 postinoculation.
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“Statistical methods” below were calculated. The AUCs and decay rates of 2 groups
were compared using the two-sample t test and Wilcoxon rank sum test (WRS). As
medroxyprogesterone acetate treatment had no effect of HSV-2 DNA shedding in RM
(statistical data not shown), these 2 animal groups were combined in a subsequent
analysis to compare HSV-2 DNA shedding in animals inoculated with live HSV-2 (groups
2 and 3) versus animals inoculated with heat-inactivated HSV-2 (group 5).
Significantly less HSV-2 DNA was shed in group 5 than in groups 2 and 3 from day
0.5 to 39.5 p.i. as determined by comparison of AUCs by the t test (P 0.04) but not the
WRS (P 0.112), and the decay rate of HSV DNA level was significantly higher in the
inactivated HSV animals (group 5) than in live HSV-2 animals (groups 2 and 3) after
the second inoculation (days 28.5 to 39.5 p.i.) by both the t test (P 0.003) and the WRS
(P 0.007). Thus, the results of these statistical analysis support the conclusion that
while much of the HSV-2 DNA detected in the first 12 days after inoculation is due to
decay of the virus in the inoculum, productive viral replication also contributes to viral
shedding in this phase. Further productive viral replication accounts for all the HSV-2 DNA
shedding outside the initial postinoculation period of intense viral shedding.
Proteomic analysis of CVS after vaginal inoculation of RM with live HSV-2 or
heat-inactivated virus. CVS samples collected from RM in groups 2, 3, 4, and 5 were
analyzed by mass spectrometry to identify protein signatures that were uniquely
associated with live HSV-2 replication within the vaginal mucosa. A total of 526 proteins
were detected across all time points from live HSV-2-challenged RM (groups 2, 3, and
4) samples, while 726 proteins were detected from inactivated HSV-2-challenged RM
(group 5) samples (Fig. 5A). Protein expression was evaluated against baseline and the
prechallenge time point within each study group. Proteome alterations were observed
on days 1, 2, and 29 in CVS from RM inoculated with live HSV-2 (groups 2, 3, and 4),
which were significant after multiple hypotheses testing correction. However, by 7 days
p.i. (days 7 and 35), the proteome was not significantly different than the day 0
proteome (Fig. 5B). Critically, no significant changes were observed after inactivated
HSV-2 challenge (group 5) at any time point (Fig. 5B). Functional enrichment analysis
was performed on proteins differentially expressed after live HSV-2 challenge using the
Gene Ontology database; this analysis showed that inflammation and wound-healing
processes were significantly associated with these proteins. Visualization by hierarchical
clustering showed a clear increase in these inflammatory proteins at days 1 and 2 after
live HSV-2 exposure (Fig. 5C). The top three unique functions enriched on days 1, 2, and
29 are displayed (Fig. 5D). Proteins involved in wounding responses, inflammation, and
antimicrobial defense were enriched at all three of these time points postchallenge
(P 0.0001) (Table 2).
Systemic HSV-2-specific T-cell responses. To determine if the group 1 animals
(inoculated 5 times) made HSV-2-specific T-cell responses, cryopreserved splenocytes
were stimulated with HSV-2 peptides pools or a lysate of mock-infected cells. HSV-2-
specific, tumor necrosis factor alpha (TNF-)- and gamma interferon (IFN-)-secreting
CD4 and CD8 T cells were detected by flow cytometric intracellular cytokine staining
(Fig. 6). All 4 animals made easily detectable T-cell responses to a wide variety of HSV-2
antigens, including the capsid/tegument and surface glycoproteins. Two of the four
animals made very strong anti-HSV-2 responses (5% of a T-cell subset), but one these
animals (35667) had a response dominated by CD4 T cells, and in the other animal
(34806) the response was made largely by CD8 T cells (Fig. 6).
To determine if the group 2 animals made HSV-2-specific T-cell responses, aliquots
of cryopreserved peripheral blood mononuclear cells (PBMC) collected before HSV-2
inoculation (day 0) and at day 43 p.i. were stimulated with HSV-2 peptide pools, lysates
of HSV-2-infected cells, and a lysate of mock-infected cells. HSV-2-specific, TNF-- and
IFN--secreting CD4 and CD8 T cells were detected by flow cytometry and intracel-
lular cytokine staining (Fig. 7). All 6 animals made readily detectable T-cell responses to
HSV-2 antigens, but there was wide variation in the strength and breadth of the
responses (Fig. 7). One animal (39406) made very weak CD4 and CD8 T-cell re-
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sponses to all HSV-2 antigens tested, and 2 animals (34099 and 33869) had relatively
strong HSV-2-specific T-cell responses (Fig. 7). As expected, HSV-2-specific CD4 T-cell
responses were strongest and most consistent in PBMC stimulated with the HSV-2-
infected cell lysates, but peptide pools elicited the strongest HSV-2-specific CD8 T-cell
responses (Fig. 7).
HSV-2-specific antibody responses. Acute- and convalescent-phase sera collected
from days 42 to 350 p.i. were analyzed. Western blotting and enzyme-linked immu-
FIG 5 Mucosal wound healing and inflammatory responses were observed in CVS after live HSV-2 inoculation. (A) Using mass spectrometry, a total of 526 and
726 proteins were detected in CVS samples from live HSV-2-challenged RM (groups 2, 3, and 4; n  12) and inactivated HSV-2-challenged macaques (group
5; n  3), respectively. (B) Significantly differentially expressed proteins were identified on days 1 and 2 after live HSV-2 challenge relative to baseline (day 0).
The proportion of proteins that were significantly different at an unadjusted P value of 0.05 (pink) and adjusted P value of 0.05 (FDR  5% [green]) are
displayed. Significant protein changes were also observed 1 day after a second live HSV-2 challenge (day 29). No significant protein alterations were observed
after challenge with inactivated HSV-2 (P 0.05). (C) Differentially expressed proteins in CVS of 12 RM (groups 2, 3, and 4) after live HSV-2 challenge displayed
as a heat map. (D) The top 3 functions associated with proteins that were significantly altered in groups 2, 3, and 4 on days 1 (purple bars), 2 (green bars), and
29 (red bars) by live HSV-2 challenge were related to wound healing, innate immunity, and inflammation.
Lo et al. Journal of Virology
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nosorbent assays (ELISAs) using whole HSV-2 antigen did not detect HSV-2-specific IgG
in plasma of the 4 inoculated animals that were tested (see Table S3 in the supple-
mental material). IgG antibodies to glycoprotein G (gG) of HSV-2 were detected in 2
animals (35633 and 40371) using the HerpeSelect ELISA, while a Luminex-based assay
detected IgG antibodies to gD2 of HSV-2 in 3 animals (35633, 39406, and 34889) (Table
S3). One of these animals (35633) also demonstrated rising titers to the capsid protein
UL-19. This low frequency of seroconversion to HSV-2 among the infected RM was
unexpected but may reflect the relatively low levels of HSV-2 replication in the RM.
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FIG 6 HSV-2-specific CD4 and CD8 T-cell responses in splenocytes of four HSV-2-infected rhesus macaques (group 1). Splenocytes of four monkeys were
stimulated with various HSV-2 peptide pools. HSV-2-specific, TNF-- and IFN--secreting CD4 and CD8 T cells were detected by flow cytometric intracellular
cytokine staining. (A) Representative data from 2 animals (35667 and 34806) stimulated with various HSV-2 peptide pools or a mock cellular lysate as indicated
above each dot plot. For each animal, CD4 T-cell responses are on the left and CD8 T-cell responses are on the right. (B) Frequency of CD4 T cells producing
TNF- and IFN- in response to stimulation with the peptide pools indicated on the x axis. (C) Frequency of CD8 T cells producing TNF- and IFN- in response
to stimulation with the peptide pools indicated on the x axis.
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HSV-2 DNA in neural tissue. Lastly, we tested for the presence of HSV-2 DNA and
HSV-2 RNA in tissues (vulva, vagina, cervix, pelvic nerves, and sacral, lumbar, thoracic,
and cervical ganglia) collected at necropsy from the group 1, group 2, and group 5
animals, as well as cervical biopsy specimens collected at 7 days after the first HSV-2
inoculation from group 1 and group 2 animals. Tissue was homogenized, and DNA was
extracted and subjected to quantitative PCR (qPCR) for HSV-2 DNA (Table 1). Group 1
animals were necropsied at day 72, 14 to 18 days after the last HSV-2 inoculation, and
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FIG 7 HSV-2-specific CD4 and CD8 T-cell responses in PBMC from six HSV-2-infected rhesus macaques (group 2). PBMC collected prior to HSV-2 inoculation
and 43 days after the first HSV-2 inoculation were stimulated with a lysate of HSV-2-infected cells or various HSV-2 peptide pools. HSV-2-specific, TNF-- and
IFN--secreting CD4 and CD8 T cells were detected by flow cytometric intracellular cytokine staining. (A) Representative data from 6 animals stimulated with
various HSV-2 peptide pools or HSV-2 lysates as indicated above each dot plot. For each time point, CD4 T-cell responses are on the left and CD8 T-cell
responses are on the right. (B) Frequency of CD4 T cells in day 63 PBMC producing TNF- and IFN- in response to stimulation with the HSV-2 lysates and
HSV-2 peptide pools indicated on the x axis. (C) Frequency of CD8 T cells in day 63 PBMC producing TNF- and IFN- in response to stimulation with the HSV-2
lysates and HSV-2 peptide pools indicated on the x axis.
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group 2 animals were necropsied at days 50 to 57, 3 weeks after the last inoculation. All
3 group 5 animals receiving heat-inactivated HSV-2 were necropsied between days 161
and 211 p.i. As shown in Table 1, although we detected HSV DNA in sacral and/or
autonomic ganglia (pelvic nerve) or sacral sympathetic trunk in 7 of the 10 animals that
received live virus challenges; HSV DNA was not detected in neural tissue at necropsy
in any of the animals receiving heat-inactivated virus challenge. Variability in titer was
seen between sites and animals (Table 1).
HSV DNA was present in cervical tissue at day 7 in 4 of 10 group 1 and group 2
animals at necropsy, indicating cervical tissue infection (Table 1), even at times in which
superficial cervical swabs were negative. HSV-2 DNA was not detected in any of the 18
vaginal or cervical tissues collected at necropsy from group 5 animals (Table 1). HSV
mRNA for the latency-associated transcript (LAT) was not detected in the nervous tissue
samples of any RM using quantitative reverse transcription-PCR (RT-PCR).
DISCUSSION
Our data demonstrate acute HSV-2 infection, neural infection/persistence, and
spontaneous and subclinical reactivation in RM for about 40 days after virus inocula-
tion. We found that after vaginal inoculation with HSV-2, RM develop a subclinical
infection with persistence of vDNA in the genital tract and nervous tissues, histologic
evidence of viral pathology in the genital tract in the first few weeks after inoculation,
transient increased expression of proteins associated with wound healing, innate
immunity, and inflammation, and spontaneous intermittent low-level virus shedding in
genital secretions up to 30 days after virus inoculation. Despite evidence of persistent
ganglionic infection on autopsy, the frequency of HSV-2 shedding seemed to decrease
as the interval between inoculation and sampling increased, suggesting that either
HSV-2 reactivation is less frequent and spread more restricted or viral clearance is
enhanced in RM compared to humans, in whom reactivation is quite frequent in the
early time periods post primary acquisition (23).
Because the stratified squamous epithelia of the perineum, vagina, and ectocervix
are the major sites of HSV-2 replication, determining the levels of virus shed in genital
swabs collected at regular intervals is the standard method used to characterize the
virology of HSV-2 infection in women. By comparing vDNA levels in secretions of
groups of RM inoculated with aliquots of either active or inactivated HSV-2, we are able
to conclude that while much of the HSV-2 DNA detected in the first 7 days after
inoculation is due to decay of the virus inoculum, some shedding of DNA is associated
with productive viral replication. Further, productive viral replication accounts for all
the HSV-2 DNA shedding outside the initial postinoculation period. Although the
animals were inoculated with a mixture of at least HSV-2 strains, there was not a
detectable difference in the ability of any strain to infect RM, suggesting that none of
these HSV-2 strains has a replicative advantage in RM. Recent studies of women using
genital secretions collected daily have shown that brief episodes of clinically silent
HSV-2 shedding are common (24, 25). Thus, for approximately 40 days after virus
inoculation, the pattern of virus shedding found in RM is similar to that found in HSV-2
asymptomatic women.
Although we are unaware of any studies describing the CVS proteome in women
with acute HSV-2 infection, the pattern of protein expression in CVS of RM after HSV-2
inoculation which included proteins involved in the response to epithelial damage,
antimicrobial defense, and inflammation that were enriched from 1 to 7 days after live
HSV-2 inoculation (Fig. 5) is consistent with acute HSV-2 infection. Of note, the most
striking responses occurred at 1 and 2 days p.i., with a trend toward a return to baseline
protein expression by 7 days p.i. This pattern is consistent with an acute viral infection
of the female reproductive tract with epithelial damage followed by repair and an
ongoing immune and inflammatory response. These results confirm that the RM
became infected with HSV-2, as changes in the CVS proteome were not seen in RM
inoculated with killed HSV-2. The histopathology in cervical biopsy tissues and the
genital tissues collected at necropsy was consistent with HSV-2 infection (subacute
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inflammatory infiltrates, intraepithelial vesicles and microulcers, and degenerating
epithelial cells, including some with intranuclear inclusions) (26). HSV-2 DNA was
consistently found in the same samples, confirming the presence of HSV-2 infection
and related pathology in the genital tract of RM.
The detection of HSV antigen and DNA in tissue from inoculated RM strengthens the
conclusion that the RM were infected by HSV-2. HSV-2 infects nervous system tissues
in humans, especially spinal ganglia, where replication is generally limited, and clinical
signs generally associated with viral infection of the nervous system are rare despite the
lifelong persistence of the infection. Tissues from 10 animals were collected at nec-
ropsy, and HSV-2 DNA was detected in the peripheral nervous system in 7 of the 10
animals, including pelvic nerves and sympathetic trunk in 2 of the 10 (Table 1). While
we detected HSV-2 DNA in these samples, we did not assay whether we could recover
virus from neural tissue by cocultivation, nor could we demonstrate RNA transcription
for LAT. Future studies will be needed to define the metabolic state of HSV DNA in
neural tissue of RM.
All 16 animals inoculated with live HSV-2 became infected and exhibited intermit-
tent viral shedding, indicative of in vivo replication. The level of vDNA shed tended to
be lower in positive genital swabs than in humans, CVS samples collected more than
40 days p.i. were never HSV-2 DNA positive, and none of the animals had clinical signs
of HSV-2 infection. These data suggest that although RM became infected with HSV-2
after vaginal inoculation, most animals supported only moderate levels of HSV-2
replication (5, 6) for a limited time. It has been demonstrated that TRIM5a expression
in RM cells partially blocks HSV-2 replication in vitro (7), and this may contribute to in
vivo resistance of RM to high-level HSV-2 replication and disease. Indeed, we also found
that HSV-2 replicated poorly in LLK-MK2 cells (a rhesus macaque kidney cell line)
compared to Vero cells (a vervet monkey kidney cell line that does not produce an
antiviral interferon response) or human HeLa cells in vitro (data not shown).
The immune response to the infection was characterized by strong and consistent
T-cell responses but weak and variable antibody responses. Unexpectedly, only 30% of
the HSV-2-inoculated RM animals seroconverted during the study. This low frequency
of seroconversion may be due to the low-level, transient HSV-2 replication in the RM
that provides insufficient antigen to drive maturation of B-cell responses. Another
explanation is that longer follow-up and maturation of the B-cell response are needed
in RM. In humans, many HSV antibody responses evolve slowly over time (27). These
potential explanations are consistent with reports that antiviral therapy reduces HSV-2
shedding and retards the development of antibody to a number of HSV antigens in
women (28) and that T-cell responses to HSV are present in some HSV-2-seronegative
humans with no detectable virus shedding (29). Of note, at assignment to the study, all
RM were negative for herpesvirus simiae (herpes B virus), and they had a variety of MHC
and TRIM5a haplotypes (data not shown). However, there was no evidence of clinical
herpesvirus disease in any of the HSV-2-infected macaques, and we did not detect
macroscopic ulcers in the genital tract or sustained periods of high-level virus shedding
in the animals. The RM model we describe here has many characteristics that are found
in HSV-2 infection of immunocompetent women: spontaneous subclinical genital
herpes, including the highly variable frequency of virus shedding between animals, and
sporadic reactivation in individual animals. Whether long-term reactivation takes place
over extended periods of follow-up requires further study.
Neither transient CD8 lymphocyte (T cell and NK cell) depletion nor medroxy-
progesterone acetate treatment of RM prior to HSV-2 inoculation enhanced virus
replication or shedding. Although both of these experiments involved very small
numbers of animals, it was apparent that there was not a dramatic effect on HSV-2
infection in any of the treated animals. Several caveats apply to the CD8 depletion
experiments. The RM were HSV-2-naive animals that had not made HSV-2-specific T-cell
responses, so NK cells that lyse virus-infected cells due to decreased MHC-I expression
on the surface of infected cells were the only antiviral effector mechanism that could
have been affected by the preinoculation depletion of CD8 T cells. Future studies will
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include depletion of CD8 cells from chronically infected animals to determine if the
cells have a role in suppressing HSV-2 replication at later stages. However, this
approach has its limitations because anti-CD8 treatment does not deplete tissue-
resident T cells (22), which are likely the cells most involved in suppressing viral
replication (8, 30).
Our results may explain why prior attempts to infect RM with HSV have largely failed
(10, 11). Without the twice-daily CVS sample collection, use of heat-killed HSV-2 to
inoculate control animals, CVS proteomics, and sensitive T-cell assays, we would have
been unable to conclude that the RM in this study became infected with HSV-2.
Consistent to some degree with the results reported here, Crostarosa et al. reported
that RM became infected after experimental vaginal HSV-2 inoculation and made poor
HSV-2 antibody responses (13). However, they also reported that months after HSV-2
inoculation, viral DNA was regularly detected in genital swabs collected over a few days
(13), suggesting that virus shedding was more persistent and consistent than in the
present study.
In summary, all 16 RM that were vaginally inoculated with HSV-2 developed acute
HSV-2 infection evidenced by viral shedding in genital secretions, increased expression
of proteins associated with tissue damage and inflammation in the genital tract, and
tissue-based evidence of HSV-2 replication in the genital tract. Importantly, sporadic
HSV-2 DNA shedding in genital secretions for 40 days p.i. provided evidence of tran-
sient reactivation of virus replication in 13 of 16 animals. The HSV-2 animals devel-
oped an impressive T-cell response to a wide variety of viral antigens; some animals
developed antibodies to capsid and surface glycoproteins, and we detected evidence
of HSV-2 DNA in sensory and autonomic ganglia. The intense multifocal inflammatory
response in the genital tract during both acute and chronic infection provides optimism
that the model may be a useful one in dissecting the mechanisms underlying immune
control of HSV-2 in mucosal surfaces. The presence of viral antigen and immune cells
in the mucosa provide an opportunity to study the battlefield between the host and the
virus and offers the potential of uncovering new insights about the pathogenesis and
immunobiology of human HSV infections.
MATERIALS AND METHODS
Animals. Nineteen mature (5 years old), clinically healthy female RM (Macaca mulatta) with at least
one term pregnancy and regular menstrual cycles were used in this study. All monkeys were selected
from a specific-pathogen-free colony (SPF) that is seronegative for herpes B virus, simian T-cell lympho-
tropic virus type 1, simian retrovirus, and SIV. The serologic strategy for screening RM for herpes B virus
infection has been described previously (31). All monkeys were housed in the California National Primate
Research Center in accordance with the American Association for Accreditation of Laboratory Animal
Care standards and were trained to receive vaginal swabs without sedation. The Institutional Animal Care
and Use Committee of the University of California, Davis, approved all protocols in these experiments.
HSV-2 isolates and vaginal HSV-2 inoculation. Wild-type laboratory HSV-2 strains 186, 333, and G
were used in this study because they have been widely used in mouse and guinea pig studies and they
are pathogenic in these species (32–37). The HSV-2 186 strain was obtained from D. Knipe by D. Knoelle,
and strain 333 was obtained from L. Corey. Both strains were minimally passaged (2 or 3 times) in Vero
cells before expansion into a stock as described below. The HSV-2 G strain was purchased from the ATCC.
Virus stocks of all HSV-2 strains were expanded in Vero cells and contained1 107 PFU/ml. To produce
the stocks, supernatants from Vero cell cultures were harvested, pooled, and spun at 300  g for 10 min
to remove cellular debris. Clarified supernatants were aliquoted and frozen at 80°C until use. To
inactivate HSV-2 for animal inoculations, aliquots of the stocks were pooled and heated to 56°C for 1 h
and then frozen at 80°C overnight. This procedure was repeated 5 times for the HSV-2 pools used to
expose animals 38044 and 37349 and 3 times for the HSV-2 pools used to expose animal 40257. We
found that all the live stocks contained approximately 109.5 vDNA copies/ml, while the DNA concentra-
tion in pooled killed HSV-2 stocks was higher (approximately 1010 vDNA copies/ml), presumably due to
loss (sublimation/evaporation) of some media during the inactivation process.
For all intravaginal inoculations, 1 ml of total virus stock was introduced into the vaginal canal with
a 1-ml needleless syringe while the animal was sedated and in sternal recumbency.
Medroxyprogesterone acetate treatment. As previously described (38), 4 weeks prior to and on the
day of HSV-2 inoculation, medroxyprogesterone acetate (30 mg/animal) was administered by intramus-
cular injection to the 4 RM in group 3.
In vivo depletion of CD8 lymphocytes (CD8 T cells and NK cells). Using methods previously
described (39, 40), group 4 RM (n  2) were treated with a CD8 lymphocyte (CD8 T cells and NK
cells)-depleting complementarity-determining region (CDR)-grafted rhesus IgG1 MAb, MT807R1, and the
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neutralizing CDR-grafted rhesus IgG1 anti-IL-15 MAb M111R1. The MT807R1 MAb was derived from a
mouse anti-human CD8 MAb (41), and the M111R1 MAb was derived from a mouse anti-human
anti-IL-15 MAb. The anti-IL-15 antibody prevents homeostatic proliferation of other lymphocyte subsets
during CD8 lymphocyte depletion (42). Both MAbs (50 mg/kg of body weight) were administered by
subcutaneous injection 3 days before and the day of HSV-2 inoculation. The NIH Nonhuman Primate
Reagent Resource, University of Massachusetts Medical School (Boston, MA), provided the M111R1 and
MT807R1 MAbs used in these studies.
Collection of CVS samples, vaginal swabs, and tissues. The schedule of genital tract collections is
detailed in Tables S1 and S2. Postinoculation cervical sections were collected twice daily (6-h intervals),
5 days/week, by swabbing the ectocervix, vagina, and perineum. All monkeys were trained to accept
twice-daily vaginal swabs with food rewards and without sedation. Two vaginal swabs were collected
simultaneously twice daily from HSV-2 inoculation to necropsy. One swab was stored in UTM viral
transport medium (Copan Diagnostics, Murrieta, CA) for virus isolation, while the other swab was stored
in AVL buffer (Qiagen, Germantown, MD) for viral nucleic acid analysis. In addition, cervicovaginal
secretion (CVS) samples were collected weekly by vigorously infusing 6 ml of sterile phosphate-buffered
saline (PBS) into the vaginal canal and then aspirating as much of the instilled volume as possible
while the RM were immobilized. Care was taken to ensure that the cervical mucus was included in the
lavage fluid and that no trauma to the mucosa occurred during the procedure. Two-thirds of the CVS
sample was snap-frozen on dry ice and stored at 80°C until analysis. The remainder was spun, and the
supernatant was treated with 10 protease inhibitor (Roche) and subsequently used for cytokine and
chemokine quantitation. The sample collection and preparation procedure resulted in at least a 10-fold
dilution of the CVS. All samples were stored at80°C until analysis. Genital tract tissues (vaginal mucosa,
vulva, and perineum) and nervous tissues (including pelvic nerves, sacral sympathetic trunk, dorsal root
ganglia, and sacral, lumbar, thoracic, and cervical spinal cords) were collected at the time of necropsy.
Tissues were stored in RNAlater, which preserves all nucleic acids (Ambion, Austin, TX), and kept at20°C
until DNA extraction.
Quantitative real-time PCR. In brief, PCR to detect HSV-2 was performed in a validated quantitative
PCR assay as previously described (43–46). DNA samples were prepared by using the QiaAmp DNA blood
kit (Qiagen) according to the manufacturer’s instructions. Quantitative real-time PCR targeting HSV-2 gB
DNA and HSV-2 polymerase DNA was used to determine the frequency and level HSV-2 DNA in vaginal
swabs and tissues collected at necropsy. The cutoff utilized was 1 DNA copy/reaction, or 50 copies/l of
swab sample. To differentiate HSV-2 strains 186 and 333, we use primers and probes as follows:
UL24 565F, GCATGTCTTTAGCTCCAGGATGA; UL24 565R, CCGCCCAGACTGCATCTG; UL24 565A,
6-carboxyfluorescein (FAM)-ATTGGCGAATTCAAA-MGBNFQ; and UL24 565G, VIC-TTGGCGAATTCGAA-
MGBNFQ. We estimated cell number in a tissue sample by quantifying the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) DNA copy number and dividing by 2. DNA genomes were measured with a
qPCR primer-probe cocktail amplifying the human GAPDH gene (ABI). The PCR results are reported as
HSV-2 DNA copies/swab for cervicovaginal swab samples, or HSV-2 DNA copies/million cells for tissue
samples.
HSV-2 isolation. To isolate infectious HSV-2, eluents of vaginal swabs and CVS fluids were filtered,
then added to human diploid fibroblasts and Vero cell cultures, and monitored for signs of HSV-2
replication as described previously (47).
CVS proteome analysis. Mass spectrometry was utilized to characterize host proteins in CVS as
described previously (48, 49). CVS collected from macaques challenged with live (n 12; groups 2, 3, and
4) and inactivated (n  3; group 5) HSV-2 were analyzed in two independent mass spectrometry
experiments. Briefly, 50 g of protein from each sample was processed using filter-aided sample
preparation, and isolated peptides were digested with trypsin. Peptides were cleaned of salts and
detergents using reversed-phase liquid chromatography (high pH RP, Agilent 1200 series microflow
pump, and Water XBridge column) and analyzed by label-free tandem mass spectrometry using an
Orbitrap Q-Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, MA). Mass spectrometry data
were run through Progenesis QI software using default parameters (Nonlinear Dynamics, Durham, NC).
Peptide identity searches were performed using Mascot Daemon v2.4.0 (Matrix Science, Boston, MA)
against the UniprotKB/Swiss-Prot (2015) database, restricting taxonomy to both the Homo and Macaca
genera. Host protein identifications were restricted to high-confidence hits using Scaffold (v4.4.1;
Proteome Software, Portland, OR; confidence thresholds, 0.1% false-discovery rate [FDR] for peptide
identification and 1% FDR for protein identification, 2 peptides identified). Significant changes in
protein expression relative to prechallenge time points (day 0) were assessed using paired t tests and
were adjusted for multiple-hypothesis testing using the Benjamini-Hochberg method. Functional en-
richment analysis was performed using DAVID Bioinformatics Resources (6.7) against the Gene Ontology
Database (50).
Intracellular cytokine staining. Flow cytometric intracellular cytokine analysis was used to detect
HSV-specific CD8 and CD4 T-cell responses measured in cryopreserved splenocytes or PBMC prepa-
rations as previously described (51, 52). Briefly, isolated mononuclear cells were incubated with HSV
lysate (HSV-2 isolates 186 and 333) or HSV gene-specific peptide open reading frame pools (ICP4, gD-1,
UL25, and UL46; 15-mers overlapping by 11 at 2 g/ml per peptide) and the costimulatory molecules
CD28 and CD49d (BD Biosciences, San Jose, CA) alone for 1 h, followed by addition of brefeldin A
(Sigma-Aldrich) for an additional 8 h. Costimulation with uninfected cell lysates (mock) served as a
background control. The next day, stimulated cells were stained with fluorochrome-conjugated MAbs,
including SP34-2 (CD3; Pacific Blue), L200 (CD4; AmCyan), SK-1 (CD8; peridinin chlorophyll protein
[PerCP]-Cy5.5), MAB11 (TNF-; phycoerythrin [PE]), B27 (IFN-; allophycocyanin [APC]) FN50 (CD69;
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PE-Texas Red). Data were collected on an LSR-II (BD Biosciences). Analysis was performed using FlowJo
software (Tree Star, Ashland, OR) and graphed using GraphPad Prism. In all cases, gating on the
lymphocyte population was determined by the separation of the CD3 T-cell subset and progressive
gating on CD4 and CD8 T-cell subsets. Antigen-specific response frequencies for the CD4 and CD8
T-cell populations were determined from intracellular expression of either or both IFN- and TNF-
above background (mock).
HSV-2-specific ELISA. Plasma was also tested for HSV-2-specific antibodies with a whole-virus ELISA
modified to detect nonhuman primate IgG. In brief, ELISA plates were coated with a 1:1 mixture of
UV-inactivated, Vero cell-associated HSV-2 strain 186 and 333 lysates at a dilution of 1:200 each or control
Vero cell lysate. After blocking, plasma samples were loaded for 2 h at room temperature. Controls for
anti-HSV-2 binding included pre- and postvaccination mouse serum from prior studies (53), and controls
for detection of macaque IgG were serum from animals before and after vaccination with vaccinia virus
vector kindly provided by Shu-lock Hu, University of Washington. For the latter, a lysate of vaccinia virus
grown in BSC-40 cells or control uninfected BSC-40 lysate was prepared as described previously (54) and
used to coat ELISA plates. After washes, macaque IgG was detected with a 1:10,000 dilution of
horseradish peroxidase (HRP)-conjugated affinity purified goat anti-monkey IgG (KPL, Gaithersburg, MD;
part 074-11-021), while murine IgG was detected as described previously (53). After further washes,
tetramethylbenzidine (TMB) substrate (KPL; part 50 to 76-00) was used per the manufacturer, reactions
were stopped with phosphoric acid, and the optical density at 450 nm (OD450) was recorded. The
detection of specific macaque IgG was confirmed by the detection of high levels of macaque anti-
vaccinia virus IgG in sera from post- but not prevaccine sera from animals vaccinated with a vaccinia virus
vector vaccine in a vaccinia virus antigen ELISA, with no binding to control BSC-40 cell antigen (data not
shown). The antigenicity of the HSV-2 preparations used was confirmed by brisk binding of HSV-2-
specific murine IgG to the HSV-2 antigen, with no binding to Vero cell control antigen (data not shown).
Binding antibodies to HSV. HSV antibodies in sera were also assessed with a Luminex-based assay.
MagPlex microspheres (Luminex Corp.) were coated with 10 g/ml of recombinant HSV-2 gD2, UL19,
UL25, gJ, and ICP47 using an antibody coupling kit (Luminex Corp.) according to the manufacturer’s
instructions and then blocked for a minimum of 1 h in 5% powdered milk–0.1% Tween 20–PBS. Primate
plasma was then diluted 1:5, 1:25, and 1:125 in 1% milk–0.1% Tween 20–PBS assay buffer and incubated
for 2 h with 2,500 each gD2, UL19, UL25, gJ, and ICP47 antigen-coated microspheres. Microspheres were
washed three times in 0.1% Tween 20–PBS and then incubated with either a 1:500 dilution of anti-human
IgG PE-conjugated secondary antibody (Southern Biotech; 2084-09) or 1:1,000 dilution of anti-monkey
IgG biotin-conjugated secondary antibody (Nordic Immunological Laboratories, Tilburg, Netherlands) for
1 h. Microspheres were washed three times with 0.1% Tween 20–PBS. An additional incubation with
8 g/ml of streptavidin-PE (Life Technologies; S-866) for 30 min followed by three washes with 0.1%
Tween 20 PBS was performed for anti-monkey IgG secondary antibody microspheres. All microspheres
were resuspended in 0.1% bovine serum albumin (BSA)–0.1% Tween 20–PBS and analyzed for antibody
binding using a Luminex 200 instrument with MasterPlex CT software (Luminex Corp.).
HerpeSelect 2 ELISA. Heparinized plasma was tested for anti-HSV-2 glycoprotein G-specific IgG
antibodies with a commercial kit, HerpeSelect 2 ELISA IgG (Focus Diagnostics), according to the
manufacturer’s instructions, except that a peroxidase-conjugated goat anti-monkey IgG Fc polyclonal
serum (Nordic Immunological Laboratories) was used as the secondary antibody.
Immunohistochemistry/immunofluorescence. To detect cell types and HSV-2 antigen-positive
cells in tissue sections, immunohistochemistry or immunofluorescence was used. Tissue was snap-frozen
in optimum cutting temperature compound (OCT) (Tissue-Tek; Sakura Finetek USA, Inc., Torrance, CA)
and stored at80°C until use. The frozen tissue was sectioned into 8-m-thick slices for hematoxylin and
eosin (H&E) histopathological analysis and immunofluorescence staining as described previously (30).
Briefly, tissue sections were fixed and permeabilized in acetone before applying antibodies specific to
HSV (rabbit polyclonal; Dako), CD4 (L200; BD Biosciences), and CD8 (RPA-T8; BD Biosciences). In dual
staining, the tyramide signal amplification (TSA; Invitrogen) method was used for the CD4 antibody
detection, followed by incubation with CD8-	lexa Fluor 647 (AF647) overnight. All tissue sections were
counterstained with 4=,6-diamidino-2-phenylindole (DAPI; Fluka) before mounting in Mowiol 40 to 88
containing 2.5% (wt/vol) DABCO (Sigma-Aldrich, St. Louis, MO).
Histopathologic analysis. Tissues obtained by biopsy or necropsy were fixed with 4% paraformal-
dehyde, embedded in paraffin, and cut at 6 m, and the sections were stained with hematoxylin and
eosin. Slides were examined and micrographs made using a Zeiss Axiophot microscope.
Data presentation and analysis. Data were analyzed on Macintosh computers using Apple
OSX10.11.6 and GraphPad Prism version 7 (GraphPad Software, San Diego, CA), and Macintosh comput-
ers (Apple Inc., Cupertino, CA) were used to graph the data.
Statistical methods. For comparing levels of HSV-2 DNA shedding between animal groups, the area
under the curve (AUC) of the HSV-2 DNA level for each animal, defined as the average HSV DNA level over
several intervals (0.5 to 28 days, 12 to 28 days, 28.5 to 39.5 days, and 0.5 to 39.5 days), was calculated. In
addition, the HSV-2 DNA level decay rate over intervals (0.5 to 28 days and 28.5 to 39.5 days) separately
was estimated for each animal based on fitting an exponential decay model for changes in DNA level
over time. The exponential decay model assumes that the DNA level for an animal    2(–T), where
T is the time from the start of the time interval,  quantifies the decay rate, and 1/ quantifies the mean
lifetime (i.e., at which the average DNA level is reduced to half its value at the beginning of the interval).
The decay rate for each animal within an interval is computed using the nonlinear least square (nls)
package (https://cran.r-project.org/). Both a two-sample t test and a Wilcoxon rank sum test (WRS) were
used to test equality in distribution of AUCs and DNA level decay rates between animal groups.
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